VA must add non-opioid pain drugs to formulary within 18 months
S. 3209 — NOPAIN for Veterans Act · Filed by Shelley Capito (R-WV) · 27 cosponsors · Introduced Nov 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the VA to add newly approved non-opioid pain medications to its formulary (list of covered drugs) within one year of FDA approval or when Medicare begins paying for them separately, whichever comes first. It defines non-opioid pain drugs as those that don't act on opioid receptors and are approved to treat acute or post-surgical pain. The bill bars the VA from using funds from the Cost of War Toxic Exposures Fund to pay for this expansion.
Why we flagged it
The bill's core function is to mandate VA inclusion of non-opioid pain medications in its formulary on a defined timeline, directly expanding treatment options for veterans. This is a straightforward public-health measure aimed at reducing opioid dependence in the VA system.
What the text implies
- The 18-month FDA-approval clock may incentivize faster VA adoption of newer drugs before Medicare payment pathways are established, potentially creating a gap where VA covers drugs before broader CMS guidance exists.
- Barring use of the Cost of War Toxic Exposures Fund (section 324) for this expansion may signal that non-opioid pain management is not classified as a war-related health need, potentially limiting funding for veterans with service-connected pain conditions.
- The bill does not specify formulary tier, prior-authorization requirements, or dosing limits, leaving implementation details to VA discretion—coverage may be nominal without clinical guidance.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Veterans gain access to a broader range of non-opioid pain-management options, addressing the opioid-addiction crisis and giving patients more treatment choices. The mandate ensures timely inclusion of FDA-approved alternatives without requiring veterans to fight for coverage on a case-by-case basis.
Who stands to gain
- pharmaceutical manufacturers of non-opioid pain medications
- FDA-approved drug developers in acute/post-surgical pain space
Named in the bill
Department of Veterans Affairs, Secretary of Veterans Affairs, Food and Drug Administration, Centers for Medicare & Medicaid Services, Cost of War Toxic Exposures Fund, Section 8125 of Title 38 USC, Section 1833(t)(16)(G) of Social Security Act, Section 416.174 of Title 42 CFR
Where it stands
27 cosponsors: 13 Democrats, 13 Republicans, 1 Independents.
- Nov 19, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Nov 19, 2025 — Referred to Senate Committee on Veterans' Affairs · Congress.gov: “Read twice and referred to the Committee on Veterans' Affairs”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,846 characters) on Aug 16, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“VA must add non-opioid pain drugs to formulary within 18 months” QuorumCivic. https://share.quorumcivic.app/bill/119/s3209 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.